Cargando…

Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases

BACKGROUND: Central nervous system (CNS) involvement contributes to significant morbidity and mortality in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) and represents a major challenge for clinicians. Liquid biopsy of cerebrospinal fluid (CSF)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siravegna, Giulia, Geuna, Elena, Mussolin, Benedetta, Crisafulli, Giovanni, Bartolini, Alice, Galizia, Danilo, Casorzo, Laura, Sarotto, Ivana, Scaltriti, Maurizio, Sapino, Anna, Bardelli, Alberto, Montemurro, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640139/ https://www.ncbi.nlm.nih.gov/pubmed/29067216 http://dx.doi.org/10.1136/esmoopen-2017-000253

Ejemplares similares

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
por: Chilà, Giovanna, et al.
Publicado: (2021)

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
por: Crisafulli, Giovanni, et al.
Publicado: (2019)

Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)
por: Pisacane, Alberto, et al.
Publicado: (2022)

Correction to: Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)
por: Pisacane, Alberto, et al.
Publicado: (2022)

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
por: Berrino, Enrico, et al.
Publicado: (2022)

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
por: Pignochino, Ymera, et al.
Publicado: (2010)

MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer
por: Petrelli, Annalisa, et al.
Publicado: (2020)

Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients
por: Berrino, Enrico, et al.
Publicado: (2021)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours
por: Bertero, L., et al.
Publicado: (2019)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance
por: Siravegna, Giulia, et al.
Publicado: (2014)

Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance
por: Crisafulli, Giovanni, et al.
Publicado: (2023)

“Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer”?
por: Kolling, Stefan, et al.
Publicado: (2020)

Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition
por: Verginelli, Federica, et al.
Publicado: (2021)

HER2 expression and efficacy of T-DM1
por: Montemurro, Filippo
Publicado: (2014)

A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer
por: Bussolati, G, et al.
Publicado: (2005)

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2022)

Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study
por: Geuna, Elena, et al.
Publicado: (2020)

Quantification of HER family receptors in breast cancer
por: Nuciforo, Paolo, et al.
Publicado: (2015)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

Underuse of Anthracyclines in Women with HER-2(+) Advanced Breast Cancer
por: Montemurro, Filippo, et al.
Publicado: (2010)

Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study
por: Montemurro, Filippo, et al.
Publicado: (2008)

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
por: Redana, Stefania, et al.
Publicado: (2010)

The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment
por: Marchiò, Caterina, et al.
Publicado: (2018)

Endothelial cell differentiation of human breast tumour stem/progenitor cells
por: Bussolati, Benedetta, et al.
Publicado: (2009)

Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report
por: Benvenuti, Silvia, et al.
Publicado: (2020)

Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases
por: Bai, Kaixuan, et al.
Publicado: (2023)

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism
por: Fuentes, Gloria, et al.
Publicado: (2011)

Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
por: Malani, Rachna, et al.
Publicado: (2020)

Infracentimetric HER-2 positive breast tumours—review of the literature
por: da Fonseca Reis Silva, Danilo, et al.
Publicado: (2015)

HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review
por: Carlsson, J, et al.
Publicado: (2004)

Clinical utility of exemestane in the treatment of breast cancer
por: Zucchini, Giorgia, et al.
Publicado: (2015)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017)

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
por: Floros, Konstantinos V., et al.
Publicado: (2021)

Single‐cell RNA sequencing reveals the characteristics of cerebrospinal fluid tumour environment in breast cancer and lung cancer leptomeningeal metastases
por: Ruan, Haoyu, et al.
Publicado: (2022)

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
por: Styczen, Hanna, et al.
Publicado: (2015)

Metastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumours.
por: Giavazzi, R., et al.
Publicado: (1980)

The concentration of desmethylmisonidazole in human tumours and in cerebrospinal fluid.
por: Dische, S., et al.
Publicado: (1981)

Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study
por: Galizia, Danilo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9la5fkds1j5a1eh49ikrmfacfe